| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
28,040,000 |
| Market
Cap: |
56.92(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.08 - $3.86 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.1 |
| Insider 6 Months : 12.1 |
| Insider 3/6 Months : 24.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Corvus Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of immune modulator product candidates to treat solid cancers, T-cell lymphomas, autoimmune diseases and infectious diseases. Co.'s lead product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. Co.'s next product candidate, CPI-818, is a selective, covalent inhibitor of ITK and is in a multi-center Phase 1/1b clinical trial in patients with various malignant T-cell lymphomas. Co.'s third product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
597,634 |
597,634 |
607,634 |
782,524 |
| Total Buy Value |
$1,034,624 |
$1,034,624 |
$1,059,124 |
$1,196,645 |
| Total People Bought |
2 |
2 |
3 |
4 |
| Total Buy Transactions |
2 |
2 |
3 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-09 |
2023-11-08 |
2023-05-10 |
2022-05-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thompson Peter A |
Director |
– • • |
2016-06-17 |
4 |
B |
$12.48 |
$153,504 |
I/I |
12,300 |
5,352,266 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-17 |
4 |
B |
$12.48 |
$153,504 |
I/I |
12,300 |
5,352,266 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-06-16 |
4 |
B |
$12.04 |
$60,200 |
I/I |
5,000 |
5,339,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-16 |
4 |
B |
$12.04 |
$60,200 |
I/I |
5,000 |
5,339,966 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-06-15 |
4 |
B |
$11.94 |
$59,700 |
I/I |
5,000 |
5,334,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-15 |
4 |
B |
$11.94 |
$59,700 |
I/I |
5,000 |
5,334,966 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-06-14 |
4 |
B |
$12.71 |
$127,100 |
I/I |
10,000 |
5,329,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-14 |
4 |
B |
$12.71 |
$127,100 |
I/I |
10,000 |
5,329,966 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-06-10 |
4 |
B |
$12.98 |
$259,600 |
I/I |
20,000 |
5,319,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-10 |
4 |
B |
$12.98 |
$259,600 |
I/I |
20,000 |
5,319,966 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-06-09 |
4 |
B |
$12.95 |
$388,500 |
I/I |
30,000 |
5,299,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-06-09 |
4 |
B |
$12.95 |
$388,500 |
I/I |
30,000 |
5,299,966 |
2.25 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-05-20 |
4 |
B |
$13.09 |
$61,732 |
I/I |
4,716 |
5,269,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • • |
2016-05-20 |
4 |
B |
$13.09 |
$61,732 |
I/I |
4,716 |
5,269,966 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • – |
2016-05-19 |
4 |
B |
$12.11 |
$31,525 |
I/I |
2,600 |
5,265,250 |
2.1 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-05-19 |
4 |
B |
$12.11 |
$31,525 |
I/I |
2,600 |
5,265,250 |
2.25 |
- |
|
| Isaly Samuel D |
Director |
– • – |
2016-05-18 |
4 |
B |
$11.55 |
$48,510 |
I/I |
4,200 |
5,262,650 |
2.1 |
- |
|
| Thompson Peter A |
Director |
– • • |
2016-05-18 |
4 |
B |
$11.55 |
$48,510 |
I/I |
4,200 |
5,262,650 |
2.25 |
- |
|
| Miller Richard A Md |
President and CEO |
• • – |
2016-05-13 |
4 |
B |
$9.94 |
$2,981 |
I/I |
300 |
1,077,293 |
2.58 |
- |
|
| Miller Richard A Md |
President and CEO |
• • – |
2016-05-12 |
4 |
B |
$10.00 |
$300,000 |
I/I |
30,000 |
1,076,993 |
2.66 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2016-05-12 |
4 |
B |
$10.00 |
$700,000 |
D/D |
70,000 |
3,224,046 |
2.45 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2016-03-29 |
4 |
B |
$15.00 |
$9,999,990 |
D/D |
666,666 |
3,154,046 |
2.45 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2016-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
2,487,380 |
2,487,380 |
|
- |
|
| Orbimed Advisors Llc |
Director |
– • • |
2016-03-29 |
4 |
B |
$15.00 |
$8,250,000 |
I/I |
550,000 |
5,258,450 |
2.25 |
- |
|
| Orbimed Advisors Llc |
Director |
– • • |
2016-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
4,708,450 |
4,708,450 |
|
- |
|
112 Records found
|
|
Page 4 of 5 |
|
|
0.07 (3.57%) 
